

1 Translocation of dense granule effectors across the parasitophorous vacuole membrane in
2 *Toxoplasma*-infected cells requires the activity of ROP17, a rhoptry protein kinase.

3

4 Michael W. Panas¹, Abel Ferrel¹, Adit Naor¹, Elizabeth Tenborg^{1,3}, Hernan A. Lorenzi² and John C.
5 Boothroyd^{1*}

6

7 ¹Department of Microbiology and Immunology

8 299 Campus Drive

9 Stanford School of Medicine

10 Stanford CA 94305-5124

11

12 ²Department of Infectious Diseases

13 J. Craig Venter Institute

14 Rockville MD 20850

15

16 ³University of California at Davis

17 School of Veterinary Medicine

18 1 Garrod Drive

19 Davis CA 95616

20

21 *Corresponding author:

22 Phone: 650-723-7984

23 Fax: 650-725-6757

24 Email: jboothr@stanford.edu

26 **Abstract**

27 *Toxoplasma gondii* tachyzoites co-opt host cell functions through introduction of a large set
 28 of rhoptry- and dense granule-derived effector proteins. These effectors reach the host cytosol
 29 through different means: direct injection for rhoptry effectors and translocation across the
 30 parasitophorous vacuolar membrane (PVM) for dense granule (GRA) effectors. The machinery that
 31 translocates these GRA effectors has recently been partially elucidated, revealing 3 components,
 32 MYR1, MYR2 and MYR3. To determine if other proteins might be involved, we returned to a library
 33 of mutants defective in GRA translocation and selected one with a partial defect, suggesting it might
 34 be in a gene encoding a new component of the machinery. Surprisingly, whole-genome sequencing
 35 revealed a missense mutation in a gene encoding a known rhoptry protein, a serine/threonine
 36 protein kinase known as ROP17. ROP17 resides on the host-cytosol side of the PVM in infected cells
 37 and has previously been known for its activity in phosphorylating and, thereby, inactivating host
 38 immunity-related GTPases. Here, we show that null or catalytically dead mutants of ROP17 are
 39 defective in GRA translocation across the PVM, but that translocation can be rescued “in *trans*” by
 40 ROP17 delivered by other tachyzoites infecting the same host cell. This strongly argues that
 41 ROP17’s role in regulating GRA translocation is carried out on the host-cytosolic side of the PVM,
 42 not within the parasites or lumen of the parasitophorous vacuole. This represents an entirely new
 43 way in which the different secretory compartments of *Toxoplasma* tachyzoites collaborate to
 44 modulate the host-parasite interaction.

45

46 **Importance**

47

48 When *Toxoplasma* infects a cell it establishes a protective parasitophorous vacuole
 49 surrounding it. While this vacuole provides protection, it also serves as a barrier to the export of
 50 parasite effector proteins that impact and take control of the host cell. Our discovery here that the
 51 parasite rhoptry protein, ROP17, is necessary for export of these effector proteins provides a
 52 distinct, novel function for ROP17 apart from its known role in protecting the vacuole. This will
 53 enable future research into ways in which we can prevent the export of effector proteins thereby
 54 preventing *Toxoplasma* from productively infecting its animal and human hosts.

55

56 Introduction

57 *Toxoplasma gondii* is an obligate intracellular parasite capable of infecting a wide range of
58 cell types in almost any warm-blooded animal. As for most *Apicomplexa*, entry into a host cell and
59 interaction with host functions once inside involves the coordinated action of at least three distinct
60 secretory compartments: micronemes, rhoptries and dense granules [1]. The small, apical
61 micronemes are the first to function in invasion, releasing adhesins onto the surface of the parasite
62 that are crucial for attachment to the host cell [2,3]. The much larger, bulb-shaped rhoptries are
63 also apically located and these somehow directly introduce their contents into the host cell at the
64 start of actual invasion [4]. Once initiated, invasion involves an invagination of the host plasma
65 membrane to form a parasitophorous vacuole (PV). This process is mediated by binding between a
66 surface-localized micronemal protein, AMA1, and RON2, a protein that starts in the rhoptry necks
67 (hence “RON”) but is introduced into the host cell to become an integral membrane protein within
68 the host plasma membrane [5-7].

69 In addition to the RON proteins, rhoptries also introduce the contents of their bulbs during
70 invasion [8,9]. These proteins, generally known as ROPs, are a set of effectors whose job generally
71 appears to be to co-opt host functions [4,10-12]. Most known ROPs are members of an extended
72 family of protein kinases and pseudokinases defined by their homology to the prototypical member
73 of the family, ROP2 [13]. Among the active ROP2-like kinases are ROP17 and ROP18 which have
74 been well studied for their role in defense against immunity-related GTPases, a set of host proteins
75 that are generated in response to interferon-gamma and that attack the parasitophorous vacuole
76 membrane (PVM) resulting in eventual death of the parasites inside [14-17]. In collaboration with
77 the pseudokinase ROP5, ROP17 and ROP18 phosphorylate IRGs which disrupts their ability to bind
78 GTP, thereby neutralizing their ability to attack the PVM [18-21]. The location of these ROPs at the
79 PVM [22,23], specifically on the host-cytosolic side of this membrane [24], perfectly positions them

80 for their role in defending against IRG attack. In addition, ROP17 has been shown to impact the host
81 transcriptional network directly by as yet unknown means [25] and to be essential for full virulence
82 in mice [26].

83 A third secretory compartment, the dense granules, also plays a key function in the
84 interaction with the host cell. The contents of these spherical organelles are known as GRAs and
85 they are released into the PV after invasion is underway [27]. Unlike rhoptry proteins, however,
86 GRAs are not injected directly into the host cytosol but instead are secreted into the PV space [28-
87 30]. Some GRA proteins are involved in elaboration of the PVM into a complex network of
88 nanotubes known as the intravacuolar network [31,32]. Others associate with or even integrate
89 into the PVM where they mediate a variety of host functions including recruitment of host
90 mitochondria [33] and activation of host NFκB [34]. A third set of GRA proteins including GRA16,
91 GRA18, GRA24, and TgIST, however, are translocated across the PVM and into the host cytosol, with
92 some eventually reaching the host nucleus where they have a profound effect on many host
93 functions [11,35]. This class of GRA proteins impact the activity of host p53 [36] p38 MAPKinase
94 [37], STAT1 signaling [38,39], beta-catenin signaling [40], E2F signaling [41], and c-Myc expression
95 [42].

96 Using a genetic screen for *Toxoplasma* genes necessary for the aforementioned host c-Myc
97 upregulation, we have previously demonstrated that the translocation of GRAs across the PVM
98 involves a set of parasite proteins that originate in dense granules or dense-granule-like organelles,
99 ultimately reaching the PVM [42,43]. These MYR (Myc Regulation) genes were identified by using
100 fluorescence-activated cell sorting (FACS) to select from a population of chemically mutagenized
101 *Toxoplasma* tachyzoites those mutants that fail to upregulate a GFP-c-Myc reporter fusion in bone
102 marrow macrophages. Whole-genome sequencing of clones from the resulting populations of
103 *Toxoplasma* mutants revealed three novel genes as necessary for the c-Myc upregulation, *MYR1*,

104 *MYR2* and *MYR3* [42,43]. *MYR1* and *MYR3* form a stable complex at the PVM [43] and it is presumed
 105 that these two proteins are part of a translocon system that mediates the movement of GRAs across
 106 this membrane. *MYR2* is also at the periphery of the PV but it has not yet been found to associate
 107 with either of the other two MYR proteins. Deletion of any one of the three *MYR* genes results in a
 108 complete loss of GRA translocation and, as expected for a mutant that cannot introduce an entire
 109 class of crucial effector proteins, $\Delta myr1$ strains have a much-reduced impact on the host
 110 transcriptome [41]; they are also substantially attenuated in a mouse model of virulence [42].

111 *A priori*, it seemed likely that more than just these three proteins would be necessary for the
 112 translocation of GRA effectors across the PVM. To address this possibility, we returned to the
 113 original library of Myr-mutants [42] and asked if any of the mutants had a partial defect which
 114 might indicate that they were defective in a gene other than *MYR1/2/3*. We report here the isolation
 115 of one such mutant which was found to have a missense mutation in *ROP17* and go on to show that
 116 a functional ROP17 within the host cell is indeed necessary for the translocation of GRA proteins
 117 across the PVM, indicating that a rhoptry-derived kinase located at the PVM plays an unanticipated
 118 role in this crucial process.

119

120 **Results**

121 We previously reported the use of a forward genetic screen to identify *Toxoplasma* genes
 122 necessary for the upregulation of mouse c-Myc expression [42]. This led to the identification of
 123 *MYR1*, *MYR2* and *MYR3*, mutants for all of which show a complete loss of GRA16- or GRA24-
 124 translocation across the PVM [42,43]. To determine if other genes might be involved, we returned
 125 to the mutant libraries and screened them for a different phenotype, *partial* loss of effector
 126 translocation. This was done by isolating 42 individual clones from the two libraries and assessing
 127 their ability to translocate HA-tagged GRA16 and MYC-tagged GRA24 to the host cell nucleus in

128 infected human foreskin fibroblasts (HFFs). Most of the mutants obtained showed an essentially
129 total loss of such translocation but one, clone MFM1.15, showed an intermediate phenotype (Fig.
130 1A, B).

131 The partial phenotype of MFM1.15 suggested that it might harbor a mutation partially
132 inactivating a gene necessary for translocation, e.g. one of the *MYR* genes, or else it might harbor a
133 mutation completely ablating expression of a novel gene that is only partly necessary for
134 translocation and the c-Myc induction. To resolve this, we first used Sanger sequencing to confirm
135 there was no mutation in the *MYR1*, *MYR2* or *MYR3* loci, and then subjected the clone to whole
136 genome sequence analysis and identified the 11 mutations shown in Fig. 1C (upper panel). None of
137 these mutations were in a known *MYR* gene but one stood out as being a missense mutation in a
138 gene encoding a known protein kinase present at the PVM, ROP17. This raised the tantalizing
139 possibility that ROP17 might play a role in the translocation of GRA proteins across the PVM.
140 Consistent with this, we returned to previous datasets and saw that a nonsense mutation in *ROP17*
141 had also been seen in one of the original screens that yielded MYR1 [42]. In this latter instance, the
142 supposed “clone” that was sequenced, MFM2.1, turned out actually to be a pair of clones, such that
143 all the mutations detected were present in only about 50% of the sequence reads. One of these
144 mutations was in a gene that was mutated in two other (true) clones analyzed in the same set and
145 so this gene was pursued and eventually shown to be essential for c-Myc upregulation and was thus
146 designated *MYR1*. At the time, we did not know which of the other mutations detected were random
147 “hitch-hiker” mutations in the *myr1* mutant vs. which might be key to the phenotype in the other
148 clone present in the MFM2.1 pair. To resolve this, we recloned MFM2.1 parasites by limiting
149 dilution and searched for mutants that had a wild type MYR1 gene. One of these was fully genome
150 sequenced and the result was mutant MFM2.1.b which was found to have the ROP17 S151*

151 mutation, consistent with a defect in ROP17 being the defect that produced the Myr⁻ phenotype
152 (Fig. 1C, lower panel).

153 The finding that *ROP17* is mutated in both MFM1.15 and MFM2.1.b strongly suggested that a
154 functional ROP17 protein might be necessary for the c-Myc upregulation. To test this, we generated
155 a knock-out of *ROP17* in an otherwise wild-type *Toxoplasma* by disrupting the open reading frame
156 of *ROP17* (*TGGT1_258580*) with insertion of the *HXGPRT* gene (Fig. 2A), confirming this disruption
157 by PCR of the locus (Fig. 2B), and assessing the translocation of known effectors in HFF cells
158 infected with the resulting mutant. Preliminary results indicated that disruption of *ROP17* does
159 indeed prevent the parasite from exporting GRA16HA and GRA24MYC from the parasitophorous
160 vacuole into the host nucleus when these constructs were transiently expressed in RH Δ *rop17*
161 tachyzoites (Fig 2C).

162 To confirm the importance of ROP17, we generated a complemented Δ *rop17* mutant in
163 which a triple HA-tagged version of ROP17 is expressed off an introduced transgene (Fig. 3A).
164 Within the parasite, ROP17HA colocalized with ROP2/3/4 at the apical end of the parasite (Fig. 3B),
165 supporting proper localization of the tagged protein. As our previous results suggested ROP17 may
166 be playing a critical role in the export of MYR-dependent proteins, we used the host c-Myc
167 regulation phenotype as a readout of successful complementation. The results (Fig. 3C) showed that
168 cells infected with the Δ *rop17* mutants show only background levels of c-Myc in the nuclei of
169 infected cells whereas cells infected with wild type and the complemented mutant show robust c-
170 Myc expression (confirmation and quantification of these results are presented further below).
171 These results thereby confirm that ROP17 is indeed necessary for host c-Myc upregulation by
172 *Toxoplasma* tachyzoites, and in combination with the defect of translocation of GRA16 and GRA24
173 this strongly suggests that ROP17 is a previously unknown player in the process whereby GRA
174 proteins cross the PVM.

Even though ROP17 is a well-studied serine/threonine protein kinase, it is possible that its role in protein translocation at the PVM is as a scaffolding protein rather than as an active kinase. To test this, we made three different versions of ROP17, each with a mutation to alanine in one of three residues known to be essential for catalysis [44-46], i.e., K312A, D436A and D454A (Fig. 4A). These mutated versions were introduced into the $\Delta rop17$ mutant where they showed the expected colocalization with ROP2/3/4 in puncta at the apical end (Figure 4B). To determine if the mutant ROP17s reached the PVM after invasion, we applied previously established conditions for partially permeabilizing infected host cells such that antibodies can reach only the PVM, not the parasites within [47]. This showed that, indeed, in cells where the control antibody (anti-SAG1) fails to detect the parasites within the PVM, anti-ROP17 efficiently stains the PVM showing that the mutant ROP17s do successfully enter the host cell and traffic to this location (Fig. 4C).

We next sought to determine if the ectopic expression of the wild type ROP17 gene and/or the mutant versions could complement the phenotypes we have observed in the ROP17-disrupted strains. When we assessed protein translocation of GRA24MYC, we observed translocation into the nucleus of ~89% of cells infected with GRA24MYC-expressing wild type parasites whereas cells infected with GRA24MYC-expressing $RH\Delta rop17$ parasites showed no such translocation (Fig. 5A). The loss of GRA24 translocation was successfully rescued when the $RH\Delta rop17$ parasites were complemented with a fully functional ROP17 but not with any of the point mutant versions of ROP17 (Fig. 5A). When we assessed c-Myc upregulation, a host phenotype associated with the translocation of MYR1-dependent effectors, we observed a similar result; c-Myc was upregulated in >90% of the nuclei of host cells infected with wild type RH and $RH\Delta rop17::ROP17HA$ parasites, but in <20% of the nuclei of host cells infected with $RH\Delta rop17$ or any of the three versions complemented with a mutation altering the trio of catalytic residues (Fig 5B, C). These results

strongly suggest that ROP17's kinase activity is necessary for its role in GRA translocation across the PVM.

Given that ROP17 ends up at the PVM in infected cells and given that this is where the known GRA translocation machinery (e.g., MYR1/2/3) is located, it seemed most likely that this is where ROP17 functions to assist in the translocation of GRA proteins. To test this directly, we took advantage of the fact that when a tachyzoite infects a cell, the ROP proteins that are injected can associate either with the PVM of that parasite or with the PVM surrounding other parasites that are also present within that cell [48]. Thus, we created a reporter parasite line that lacked ROP17 expression but was stably expressing GRA24MYC; translocation of GRA24MYC in this strain should be blocked at the PV unless ROP17 can be provided in *trans*. We then infected cultures with these RH Δ rop17::GRA24MYC parasites, followed an hour later with RH Δ myr1 parasites expressing mCherry to distinguish them from the nonfluorescent RH Δ rop17::GRA24MYC line ("Condition 1", Fig. 6A). In case the order of infection was important, we also did this experiment where we inverted the order that the two strains were added to the monolayers; i.e., we initiated the infections with the RH Δ myr1 mCherry line, followed an hour later by infection with the nonfluorescent RH Δ rop17::GRA24MYC ("Condition 2," Figure 6A). In both cases, we assessed GRA24MYC translocation in infected cells after a further 17 hours, scoring cells that were infected with either of the mutants alone or those co-infected with both. The prediction was that if ROP17's role in GRA translocation is on the host-cytosolic side of the PVM, then the Δ myr1 line would provide a functional ROP17 that could act in *trans* on the translocation machinery expressed by the Δ rop17 parasites, whereas cells infected with either strain alone would not exhibit translocation. As shown in Figure 6B, this was indeed the result obtained; cells infected with either mutant alone showed no GRA24MYC in the host nucleus, whereas ~20-22% of co-infected cells did show translocation, regardless of the order that the two strains were added to the cultures. These results

222 strongly argue that the action of ROP17 can be provided in *trans* and is needed within the host
223 cytosol, not within the parasites or within the PV space since proteins are not known to be able to
224 traffic across the PVM from host to PV or parasite (except to the lysosome for digestion [49]).

225 The data presented so far show that ROP17 is necessary for the translocation of at least two
226 GRA proteins from the PV to the host nucleus. To determine if this is true of essentially all dense
227 granule effectors that end up in the host cell, we performed RNASeq analysis on HFFs infected with
228 RH wild type vs. RH Δ *rop17* parasites at 6 hours post infection. As a control for a strain that has
229 previously been shown by RNASeq analysis to be defective in the translocation of seemingly all
230 soluble GRA effectors [41], we used a Δ *myr1* strain. The results showed substantial concordance
231 between the genes modulated in a MYR1-dependent manner and a ROP17-dependent manner. This
232 conclusion can be illustrated by Principal Component Analysis (PCA) of the host genes sets
233 generated during infection with these strains. In Figure 7A, RNASeq data for the 8 strains analyzed
234 are shown on the plot of the first and second principal component, and the individual genes along
235 with their RPKM values are displayed in Supplemental Table S1. The samples infected with
236 RH Δ *myr1* and RH Δ *rop17* cluster together closely and well apart from both mock-infected cells and
237 RH-infected cells.

238 To further explore this similarity, genes that exhibit a 2.5-fold difference during infection
239 with these mutants compared to infection with the wild type were grouped by Gene Set Enrichment
240 Analysis (GSEA). First, genes that were *increased* in cells infected with the wild type parasite (RH)
241 compared to the two mutants were analyzed by GSEA. Figure 7B shows a list of gene sets in which
242 the FDR q-value of either the RH vs. RH Δ *myr1* or the RH vs. RH Δ *rop17* was less than 10^{-5} . For each
243 of these gene sets, both the FDR q-value of the RH vs. RH Δ *myr1* (green) and RH vs. RH Δ *rop17*
244 (purple) is shown. Genes that were expressed 2.5-fold *lower* in cells infected with the wild type
245 compared to either of the mutants were also analyzed by GSEA and gene sets in which either the

FDR q-value of RH vs. RH Δ *myr1* (green) or RH vs. RH Δ *rop17* was less than 10^{-5} were plotted in Figure 7C. In both cases, almost all the gene sets that are strongly affected by the lack of *MYR1* were similarly affected by the lack of *ROP17*, although the magnitude of the effect varied somewhat. Finally, we performed a direct comparison of expression levels in cells infected with RH Δ *myr1* and cells infected with RH Δ *rop17* (instead of comparing each to the wild type-infected cells). We used GSEA to analyze genes for which expression was 2.5 fold higher or 2.5-fold lower in RH Δ *rop17*-infected cells than in RH Δ *myr1*-infected cells. The results were that in neither case was a gene set enriched with an FDR q-value of even a very relaxed threshold of 10^{-4} . Hence, the absence of *ROP17* and *MYR1* appear to have similar impacts on the infected cell and thus *ROP17* appears necessary for the action of most, probably all, GRA effectors that transit across the PVM via the MYR machinery.

Discussion

Using a genetic screen, we have identified the rhoptry-derived serine-threonine protein kinase, *ROP17*, as required for action of most if not all GRA effectors that translocate across the PVM. Using a cellular “trans” complementation assay, we have further shown that the role of *ROP17* is within the host cytosol, not within the parasite or PV space, and that *ROP17* must be catalytically active to accomplish this role. Given its location at the PVM [13,21], where other necessary elements of the translocation machinery are present, these results strongly argue that *ROP17* acts on one or other components of this machinery on the host cytosol side. Although we cannot formally exclude the possibility that *ROP17* assists GRA effectors in their trafficking across the host cytosol, from the PVM to the host nucleus, the fact that the GRA effectors that reach the host nucleus possess a conventional nuclear-localization signal (NLS) argues against this possibility as there should be no need for any additional help in their journey. Indeed, heterologous expression of

270 GRA16 and GRA24 in uninfected cells shows results in efficient trafficking to the host nucleus,
271 confirming that no parasite proteins are necessary for this last stage of their journey [36,37].

272 Given that ROP17 is a protein kinase, it seems most likely that its role in translocating GRA
273 effectors is through phosphorylation of one or more key components of the translocation
274 machinery. Phosphoproteomic analyses on cells infected with *Toxoplasma* tachyzoites revealed that
275 many parasite proteins are phosphorylated at serine and threonine residues after their secretion
276 from the parasite [50]. Among such proteins are the PVM-localized MYR1 and MYR3 that are known
277 to be required for GRA translocation [42,43]. The protein kinases that mediate these
278 phosphorylations have not yet been identified but protein phosphorylation is a well-established
279 way to regulate protein function and so such modifications might be required for PVM-localized
280 proteins like these to become activated for their respective roles. Efforts to determine the full
281 machinery involved in GRA translocation across the PVM are underway and once the full
282 complement of proteins is known, mapping of all their phosphosites and determination of which
283 such sites are dependent on which protein kinase (e.g., ROP17 or, perhaps, ROP18, another serine-
284 threonine kinase present at the PVM) and which of these sites must be phosphorylated for
285 functional translocation will be an important follow-up to the work proposed here.

286 Both ROP17 and ROP18 are involved in the inactivation of immunity-related GTPases
287 [15,16,21]. Our finding that ROP17 has at least two biological roles is similar to what has been
288 reported for ROP18; this related ROP2-family member is involved in IRG inactivation and
289 proteasomal degradation of ATF6beta, a host transcription factor that localizes to the host
290 endoplasmic reticulum (which itself is adjacent to and maybe even contiguous with the PVM [51])
291 and that is crucial to the host immune response [52]. Interestingly, it is the N-terminal region of
292 ROP18, which lies outside the conserved kinase domain, that binds to ATF6beta but an active
293 kinase domain is required for the inactivation, suggesting that ATF6beta is a substrate for

phosphorylation by ROP18 [52]. Our results add a further possible explanation for the previously reported attenuation of ROP17 mutants in a mouse model of virulence using a Type I strain [26]; i.e., the decrease in virulence could be due to some combination of a weakened defense against IRGs and the defect in GRA effector translocation reported here. A major role for the latter would be consistent with the previously reported attenuation in Type I $\Delta myr1$ strains in a similar mouse model [42].

The involvement of a rhoptry protein in the function of GRA proteins is a second example of “inter-organellar” collaboration, the first being the binding of micronemal AMA1 to rhoptry neck protein, RON2, during the invasion of tachyzoites into the host cell [53,54]. This second example wherein a rhoptry bulb protein, ROP17, somehow assists in the translocation of GRA proteins makes clear that these different secretory organelles are part of a complicated but concerted machinery used by the parasites to interact with the host cell they are infecting.

Finally, it is worth noting that the chemical mutagenesis used to generate the mutant library that yielded these *ROP17* mutants provided more information than just the fact that this protein plays an important role. By specifically looking for hypomorph mutants that showed only a partial defect we were able to identify a missense M350K mutation in ROP17 providing structure/function information, namely that this residue is important for this function of ROP17. This site is within a predicted loop region that is just N-terminal of beta-sheet 4 and well away from the active site [13,44,45]. Interestingly, this is part of a region that is highly variable between different members of the ROP2 family but is in a stretch of about 9 residues that is not present in other protein kinases [45]. This may be related to the unusual, multiple functions of these secreted kinases, perhaps in enabling them to target specific substrates at this crucial interface of host and parasite.

Materials and Methods

318 **Parasite culture**

319 *Toxoplasma gondii* RH Δ hpt [55] was used for this study. *Toxoplasma* tachyzoites were
320 maintained by serial passage in human foreskin fibroblasts (HFFs) cultured in complete Dulbecco's
321 Modified Eagle Medium (cDMEM) supplemented with 10% heat-inactivated fetal bovine serum
322 (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin and grown at 37 °C in
323 5% CO₂. Infections included in this study were performed by scraping infected monolayers and
324 lysing the host cells open using a 27-gauge needle. The released parasites were pelleted at 1500
325 rpm for 10 min, resuspended, counted using a hemocytometer, and added to confluent HFFs at the
326 multiplicity of infection (MOI) stated.

327 **Genome sequencing**

328 For whole genome sequencing on the parental RH strain (SRR2068658), MFM1.15
329 (SRR5643318), and MFM2.1b (SRS2249312) mutants, a single Illumina PE barcoded library was
330 prepared from tachyzoite gDNA. Libraries were then pooled into groups of nine samples and
331 multiplex sequenced in a single lane of an Illumina HiSeq 2000 machine to generate about 3 Gb of
332 sequencing data per sample. As the mutants were made using the Type I RH strain as the parent, the
333 sequencing reads were first quality trimmed with trimomatic and then mapped to the reference
334 assembly of the Type I GT1 strain (as present in ToxoDB v13.0) with *bowtie2* [56]. After removing
335 duplicated reads with *picard* and adjusting alignments around indels with *GATK toolkit* [57], single
336 nucleotide variants (SNVs) were called using samtools utility *mpileup* [58] requiring a minimum
337 base coverage of 5 reads and an alternative allele frequency of at least 80% or higher. Following
338 this, *SnpEff* [59] together with a gff3 annotation file from the reference GT1 strain (ToxoDB v13.0)
339 were used to classify the different types of SNVs present in each mutant. Potential change-of-
340 function SNVs that were different between any of the two mutants and both the parental and
341 reference strains were selected for further quality control and analysis.

342 **Transfections**

343 All transfections were performed using the *BTX EMC600 Electroporation System* (Harvard
344 Apparatus) or Amaxa 4D Nucleofector (Lonza) model. Tachyzoites were mechanically released in
345 PBS, pelleted, and resuspended in solution for transfection. After transfection, parasites were
346 allowed to infect HFFs in DMEM. Transfections with the *BTX EMC600* model were performed using
347 $5-10 \times 10^6$ parasites and 5-10 μg DNA in Cytomix (10 mM KPO_4 , pH 7.6, 120 mM KCl, 5 mM MgCl_2 ,
348 25 mM HEPES, 2 mM EDTA, 150 μM CaCl_2). Transfections with the Amaxa 4D model were
349 performed using $1-2 \times 10^6$ parasites in 20 μl P3 solution or $5-10 \times 10^6$ parasites in 100 μl P3
350 solution with 5-15 μg DNA. Effector translocation assays were performed by transiently
351 transfecting pHTU-GRA24MYC [43] or pGRA1-GRA16HA [43] plasmid into tachyzoites, infecting
352 monolayers of HFFs in DMEM, and fixing monolayers with formaldehyde at 16-24 hpi.

353 **Immunofluorescence microscopy**

354 Infected cells grown on glass coverslips were fixed using methanol at -20°C for 20 min or
355 4% formaldehyde at room temperature (RT) for 20 min, as stated in the text. Methanol-fixed
356 samples were washed three times for 5 min with PBS and blocked using 3% BSA in PBS for 1 hr at
357 RT. Formaldehyde-fixed samples were rinsed once with PBS, permeabilized with 0.2% Triton-X 100
358 (TTX-100) for 20 min, and then blocked as described above. GRA16HA (and other HA-tagged
359 proteins) was detected using rat anti-HA antibodies (Roche) while GRA24MYC was detected using
360 rabbit anti-MYC tag antibody 9E10 (Santa Cruz Biotechnology). This anti-MYC tag antibody does not
361 detect host c-Myc. Host c-Myc was detected using monoclonal antibody Y69, which does not cross
362 react with the MYC tag expressed by GRA24MYC. Primary antibodies were detected with goat
363 polyclonal Alexa Fluor-conjugated secondary antibodies (Invitrogen). Vectashield with DAPI stain
364 (Vector Laboratories) was used to mount the coverslips on slides. Fluorescence was detected using
365 a LSM710 inverted confocal microscope (Zeiss) or epifluorescence microscope, as stated in the text.

Images were analyzed using ImageJ. All images shown for any given condition/staining in any given comparison/dataset were obtained using identical parameters.

Quantitation of nuclear GRA24MYC

To assess the amount of GRA24MYC that translocated to the nucleus following transient transfection, phase contrast, DAPI and anti-MYC tag images were taken of 10-20 fields of view containing tachyzoites-infected HFF at 20 hours PI. Phase contrast was used to define the infected cells of these images, then ImageJ was used to define the nucleus on the DAPI-stained corresponding images, and these nuclear boundaries were then quantified for the intensity of GRA24MYC intensity on the corresponding MYC-tag stained images.

Partial Permeabilization

Parasites were syringe-released using a 27g needle and used to infect HFFs for 2 hrs, at which time the cells were washed with PBS and then fixed with 4% formaldehyde at room temperature (RT) for 20 min. Formaldehyde-fixed samples were rinsed once with PBS, permeabilized with 0.02% digitonin solution for 5 min and then blocked with 3% BSA in PBS for 1 hr at RT. Staining was performed with anti-HA (Roche) and anti-SAG1 (DG52) primary antibodies and polyclonal Alexa Fluor-conjugated secondary antibodies (Invitrogen). Partial permeabilization of a particular vacuole was determined by the exclusion of the SAG1 antibody.

Gene disruption

The RH Δ *rop17* strain was generated by disrupting the corresponding gene locus using CRISPR-Cas9 and selecting for integration of a linearized vector encoding hypoxanthine-guanine phosphoribosyl transferase (*HXGPRT*) using drug selection for 8 days using 25 μ g/mL mycophenolic acid (MPA) and 50 μ g/mL xanthine (XAN) for HXGPRT selection. Specifically, the pSAG1:U6-Cas9:sgUPRT vector [60] was modified by Q5 site-directed mutagenesis (NEB) to specify sgRNAs targeting *ROP17* (F2). The resulting sgRNA plasmid, dubbed pSAG1:U6-Cas9:sgROP17 (P1)

was transfected into the RH Δ *hpt* strain of *Toxoplasma* with pTKO2 (HXGPRT+) plasmid. The parasites were allowed to infect HFFs in 24-well plates for 24 hrs, after which the media was changed to complete DMEM supplemented with 50 μ g/ml mycophenolic acid (MPA) and 50 μ g/ml xanthine (XAN) for HXGPRT selection. The parasites were passed twice before being single cloned into 96-well plates by limiting dilution. Disruption of the gene coding regions was confirmed by PCR and sequencing of the locus.

Ectopic gene integration

The RH Δ *rop17* strain was complemented ectopically with the pGRA-ROP17-3xHA plasmid, which expresses *ROP17* off its natural promoter. To construct the pGRA-ROP17-3xHA plasmid, pGRA1_{plus}-HPT-3xHA plasmid [43] was first digested using EcoRV-HF and NcoI (New England Biolabs) for 4 hrs at 37 °C to remove the *GRA1* promoter. Product was incubated with Antarctic phosphatase (New England Biolabs) and gel-extracted. The empty vector backbone was amplified by PCR using Herculase II polymerase (Agilent) and primers 5'-CACATTTGTGTCACCCCAAATGAGAATTCGATATCAAGCTTGATCAGCAC-3' and 5'-GAGGCGGCTTTATTACAGAAGGAGCCATGGTACCCGTACGACGTCCCG-3' with each having 23 and 24 base pair overhangs to *ROP17*, respectively. The *ROP17* promoter and open reading frame were amplified from RH Δ *hpt* genomic DNA and using 5'-GTGCTGATCAAGCTTGATATCGAATTCTCATTTGGGGTGACACAAATGTG-3' and 5'-CGGGACGTCGTACGGGTACCATGGCTCCTTCTGTAATAAAGCCGCCTC-3' primers, each containing 27 or 24 base pair overhangs to the pGRA1_{plus}-HPT-3xHA plasmid backbone, respectively. Amplified backbone and *ROP17* were then assembled using the Gibson assembly master mix (New England Biolabs). ElectroMAX DH10B *E. coli* (Invitrogen) were subsequently transformed and plated to obtain single colonies of successfully assembled pGRA1-ROP17-3xHA plasmid. *ROP17* integration

was verified by PCR and sequencing using primers 5'-CACTGATCGGCTTTGTAGACTT-3' and 5'-CGCGCACGGCAGTCAGATAA-3'.

To complement RH Δ *rop17* Δ *hpt* parasites with wildtype *ROP17*, the pGRA1-ROP17-3xHA plasmid construct described previously was transfected to generate an RH Δ *rop17*::*ROP17* population. This population was selected by MPA/XAN as previously described. The resulting population was then cloned by limiting dilution and tested for ROP17-3xHA expression by Western blot and IFA.

To generate RH and RH Δ *rop17* parasite lines ectopically expressing GRA24MYC, pHTU-GRA24-3xMYC was transfected into each strain and selected using MPA/XAN as described above for 6 days.

Site-specific mutation

Site-specific point mutation of the pGRA-ROP17-3xHA plasmid was performed by creating primers 5'- GCGATATTTGTTCAACGGGTGTTGAGCAAT-3' and 5'- CAGCGCGAATGGTTGCCCTGTGGTGGG-3', 5'-GCTGTGAAACTGCAAAATTTCTTGTTGAT-3' and 5'- GCCATGAACAAGTCCGAACGCGTGGA-3', and 5'-GcCTTCACTCAAATTCTTCGTACGAATG-3' and 5'- AGAAAGTAGAAGCAATCCCGATTTATC-3' to mutate residues 312, 436, and 454, respectively, to an alanine codon within the *ROP17* open reading frame. The "Round-the-horn" site-directed mutagenesis approach was used to introduce point mutations at the aforementioned residues using the ROP17-3xHA plasmid. The PCR products were then individually ligated using a KLD Enzyme reaction kit (New England Biolabs) for 3 hours and subsequently transformed into ElectroMAX DH10B *E. coli* (Invitrogen). Single colonies for each point mutant were Miniprep (Qiagen) and sequence-verified using either 5'- GCCATGAACAAGTCCGAACGCGTGGA -3' or 5'- GCGATATTTGTTCAACGGGTGTTGAGCAAT -3'.

To generate parasite lines complemented with the catalytically inactive *ROP17*, RH Δ *rop17* parasites were transfected with the pGRA1-ROP17_K312A_-3xHA, pGRA1-ROP 17_D436A_-3xHA, or pGRA1-ROP17_D454A_-3xHA plasmid then subsequently selected for 6 days with MPA/XAN and single cloned as previously described.

Coinfection Assays

Condition 1. Confluent HFF coverslips were infected with RH Δ *rop17* parasites stably expressing GRA24-3xMYC at an MOI of 0.15. They were then pulsed at 1400 rpm and placed at 37°C and 5% CO₂ for 1 hour. Thereafter, the same sample was infected with RH Δ *myr1* constitutively expressing mCherry at a MOI of 0.15, pulsed at 1400 rpm and placed at 37°C and 5% CO₂. Infections were allowed to progress to 17-18 hours. Condition 2 was performed in the same way except the order of addition of the two strains to the host cells was reversed.

RNA extraction, library preparation, and sequencing

HFFs were serum-starved for 24 hours before infection by growth in DMEM containing 0.5% serum. They were then infected with the indicated line of tachyzoites at an MOI of 5, and at 6 hpi, 1 ml TRIzol reagent (Invitrogen) was added to each T25 and the cells were scraped. Lysates were collected and frozen at -20 °C. Total RNA was extracted following the manufacturer's instructions, with some modifications. Briefly: frozen samples were thawed on ice and 0.2 ml chloroform was added to TRIzol suspensions, which were then mixed by inverting 10 times, and incubated for 5 min. Tubes were then spun at 12,000 rpm for 15 min at 4 °C. RNA in the aqueous phase was transferred into a fresh tube and 0.5 ml absolute isopropyl alcohol was added and incubated at 4 °C for 10 min. They were then spun at 12,000 rpm for 20 min at 4 °C. After decanting the supernatants, RNA pellets were washed with 1 ml 75% ethanol and then spun at 12,000 rpm for 20 min at 4 °C. Supernatants were removed and the RNA pellets were resuspended in 30 µl RNase-free DEPC-water. RNA samples were submitted to the Stanford University Functional Genomic Facility (SFGF)

for purity analysis using the Agilent 2100 Bioanalyzer. Multiplex sequencing libraries were generated with RNA Sample Prep Kit (Illumina) according to manufacturer's instructions and pooled for a single high-throughput sequencing run using the Illumina NextSeq platform (Illumina Nextseq 500 model instrument).

RNASeq read mapping and differential expression analysis

Raw reads were uploaded onto the CLC Genomics Workbench 8.0 (Qiagen) platform for independent alignments against the human genomes (Ensembl.org/ hg19) and *Toxoplasma* Type I GT1 strain (ToxoDB-24, GT1 genome). All parameters were left at their default values. The number of total reads mapped to each genome was used to determine the RPKM (Reads Per Kilobase of transcript per Million mapped reads). Among these genes, only those with an average RPKM ratios ≥ 2.5 were counted as changed in expression.

Gene Set Enrichment Analysis (GSEA)

GSEA, available through the Broad Institute at <http://www.broadinstitute.org/gsea/index.jsp>, was the enrichment analysis software we used to determine whether defined sets of differentially expressed human genes in our experiment show statistically significant overlap with gene sets in the curated Molecular Signatures Databases (MsigDB) Hallmark gene set collection. We used the cutoff of FDR q-value $< 10^{-5}$.

PCA Analysis

To generate PCA (principle component analysis) we used <https://biit.cs.ut.ee/clustvis/#tab-9298-7> online tool. We used the RPKM values of all expressed genes to generate the PCA.

Statistical Analyses

Statistical analysis was performed with Prism version 8 software. For intensity analysis, GRA24MYC translocation was assessed by ImageJ and then differences in intensity were analyzed by one way ANOVA with a post hoc Tukey's test. Similarly, differences in the number of infected

484 host cells with nuclei staining positive for GRA24 translocation or c-Myc expression were compared
485 using a one way ANOVA with a post hoc Tukey's test.

486 Accession number

487 The RNASeq data files have been deposited in GEO under accession number GSExxxxx
488 (number available at time of publish). Data presented as transcriptomics control data, for HFFs
489 uninfected and those infected by RH and RH Δ *myr1* tachyzoites, have been published under
490 GSE122786 (Panas et al., 2019, manuscript in press at mBio).

492 Acknowledgments

493 We thank all members of our laboratory for helpful comments and input to the experiments
494 and manuscript and Melanie Espiritu for help with tissue culture and ordering. We also thank Dr.
495 Michael Reese (UT Southwestern) for help positioning the missense point mutation in the ROP17
496 secondary structure.

498 Funding

499 This project has been funded in whole or part with: federal funds from the National Institute of
500 Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services
501 under Award Numbers NIH RO1-AI21423 (JCB), NIH RO1-AI129529 (JCB), NIH U19AI110819
502 (HAL); 5T32AI007328-30 to AF; NIH/Office of the Director "Research opportunities in comparative
503 medicine" T35 grant OD010989 to LT; Gillian Fellowship HHMI to AF, and the Human Frontier
504 Science Program (LT000404/2014-L) to AN.

506 **Figure 1.** MFM1.15 shows a partial Myr⁻ phenotype and has a mutation in *ROP17*. **A.** Representative
507 immunofluorescence assay (IFA) images of HFFs infected with RH-wild type, RH Δ *myr1* or RH

mutant MFM1.15. All three parasite strains express cytosolic td-tomato (red) and were transfected with a plasmid expressing HA-tagged GRA16 which was detected by probing with anti-HA (green). Hollow arrows indicate vacuoles containing parasites expressing the GRA16HA transgene. Solid arrows indicate the nuclei in cells containing such vacuoles. Only the RH-WT-infected cells show efficient translocation of GRA16HA to the host cell nucleus. One of three biological replicates is shown. **B.** Translocation of GRA24 to the nucleus is also disrupted in mutant MFM1.15. Quantitation of nuclear GRA24MYC was assessed by anti-MYC tag staining followed by ImageJ to determine the intensity of nuclear staining in transiently transfected parasites from at least 10 random fields. The MFM1.15 mutant shows a significantly reduced nuclear signal but still more than the essentially complete lack of signal in the RH Δ *myr1* mutant. Error bars indicate standard error of the mean. *: $p < 0.05$, **: $p < 0.0001$. One of two biological replicates is shown. **C.** Mutations identified by whole genome sequencing of mutant MFM1.15 and the sub-clone MFM2.1b. Coverage is the number of reads spanning the indicated nucleotide and Variant Freq. is the fraction of reads showing the variant nucleotide relative to reference (GT1). Both mutants show mutations relative to the annotated Type I strain, GT1, in *TGGT1_258580* (*ROP17*) with a missense mutation in MFM1.15 and a nonsense mutation in MFM2.1b.

Figure 2. Deletion of *ROP17* generates a mutant parasite that cannot export GRA16 or GRA24 from the parasitophorous vacuole. **A.** Strategy for generating a disruption in *ROP17*. Plasmid pTKO2 containing HXGPRT (conferring resistance to mycophenolic acid in an otherwise Δ *hxgpirt* strain) was integrated into a cleavage site generated by Cas9 in the beginning of the *ROP17* open reading frame. Positions of the primers F and R that were used for detection of the insertion are shown. **B.** PCR data showing results of amplification with primers F and R of panel A. The wild-type locus yields a band of ~2275 bp whereas insertion of the knock-out plasmid yields a band of ~6000 bp. **C.**

532 IFA of HFFs infected with RH-WT or RH Δ *rop17* that had also been transiently transfected with
533 GRA16HA (left) or GRA24MYC (right) and then stained with anti-HA (red, left), or anti-Myc tag (red,
534 right) and DAPI (blue) to reveal the nuclei. Hollow arrows indicate parasitophorous vacuoles; solid
535 arrows indicate the nuclei in such cells. Translocation of GRA16 and GRA24 to the host nucleus is
536 seen in cells infected with RH-WT but not RH Δ *rop17* parasites (quantitation of similar such
537 experiments is shown in Fig. 5).

538

539 **Figure 3.** A wild-type copy of *ROP17* rescues the Myr⁻ phenotype of the Δ *rop17* mutant. **A.** Strategy
540 for complementing the Δ *rop17* mutants with a 3xHA-tagged wild type copy of *ROP17*. **B.** IFA
541 showing successful complementation of the Δ *rop17* mutant with a HA-tagged wild-type copy of the
542 gene. Green shows staining with anti-ROP2/3/4 as a marker for rhoptries; red shows staining for
543 the complementing ROP17-HA. **C.** IFA of HFFs infected with RH-WT, RH Δ *rop17* or
544 RH Δ *rop17::ROP17-3xHA*. Anti-HA antibody was used to detect the complementing ROP17 (green)
545 while red was used for staining of host c-Myc as an indicator of successful effector translocation,
546 and blue shows DAPI staining of the host nuclei. Hollow arrows indicate parasitophorous vacuoles;
547 solid arrows indicate the host nuclei in infected cells (quantitation of similar such experiments is
548 shown in Fig. 5).

549

550 **Figure 4.** Creation of three strains of RH Δ *rop17* containing point mutations in key catalytic
551 residues. **A.** Three different plasmids were created for the expression of point mutant variants of
552 ROP17; each expresses a *ROP17* transgene encoding an alanine substitution at one of the three
553 predicted catalytic residues: K312, D436 and D454. **B.** IFA of infected HFFs showing correct
554 trafficking of the mutated ROP17 expressed in an RH Δ *rop17* background. Anti-HA (red) detects the
555 ROP17 transgene product while anti-ROP2/3/4 (green) detects other known rhoptry proteins. **C.**

556 IFA of HFFs that were infected with the strains expressing the indicated HA-tagged version of
 557 ROP17 (WT, K312A, D436A or D454A), partially permeabilized by treatment with 0.02% digitonin,
 558 and then stained for ROP17-3xHA using anti-HA (red) or anti-SAG1 (green). The absence of SAG1
 559 staining was used to indicate that the parasitophorous vacuole was not permeabilized indicating
 560 partial permeabilization that allows antibodies to access the host cytosol but not penetrate the
 561 PVM. ROP17 is detected at the PVM in cells that are only partially permeabilized indicating the
 562 expected cytosolic exposure of the protein. A positive control of an infected cell that was fully
 563 permeabilized under these conditions is shown to confirm the anti-SAG1 staining is readily seen in
 564 such cells.

565

566 **Figure 5.** ROP17 catalytic activity appears necessary for its role in effector translocation. **A.** HFFs
 567 were infected with the indicated strains transiently expressing GRA24MYC and then 17-18 hours
 568 later the presence of GRA24MYC in the nucleus of cells infected with GRA24MYC-expressing
 569 parasites was assessed by IFA. The results are from assessment of a minimum of 94 cells and the
 570 standard error of the mean is shown. The experiment was done in biological duplicate for RH,
 571 RH Δ rop17 and RH Δ rop17::ROP17 and similar results were obtained in both. Catalytically inactive
 572 mutants were done in technical triplicate. **B.** Assessment of the effect of mutating ROP17 on host c-
 573 Myc upregulation upon infection. HFFs were infected with the indicated strain and then 20 hours
 574 later, c-Myc expression in the nucleus of infected cells was assessed using IFA and anti-c-Myc
 575 antibodies (red). Expression of the variants of ROP17-3xHA was assessed by staining with anti-HA
 576 (green). None of the three catalytic mutants rescued the Myr- phenotype of the Δ rop17 mutant.
 577 Differences were assessed by ANOVA with a post hoc Tukey's test. **: p<0.0001. **C.** Quantification of
 578 cells upregulating host c-Myc. At least 110 random fields were quantified from the slides used to
 579 produce the images shown in panel B, scoring for percentage of host nuclei in infected cells that

show host c-Myc upregulation. Differences were assessed by ANOVA with a post hoc Tukey's test.
 **: $p < 0.0001$.

582

Figure 6. ROP17's role in effector translocation occurs at the host-cytosolic side of the PVM. **A.** Conditions used for co-infection of host cells with RH Δ *rop17::GRA24MYC* and RH Δ *myr1* expressing mCherry. Infections were initiated with the indicated strain followed by addition of the second strain one hour later followed by IFA after a further 17 hours. **B.** Quantitation of the percentage of host nuclei staining positive for GRA24MYC in the cells infected with the indicated strains. Cells infected with one or other of the two mutants showed no GRA24MYC whereas those that were co-infected with both mutants showed substantial rescue in "trans." Differences were assessed by ANOVA with a post hoc Tukey's test. **: $p < 0.001$.

591

Figure 7. Disrupting *MYR1* or *ROP17* have congruent impacts on the infected host cell's transcriptome as assessed by RNASeq. **A.** Principal component analysis (PCA) of the RPKM values of HFFs mock-infected or infected with RH-WT (wild type), RH Δ *myr1*, or RH Δ *rop17* tachyzoites. On a plot of PC1 and PC2, there is close similarity of the data for cells infected with the two mutants, RH Δ *myr1* and RH Δ *rop17*, relative to the mock- or RH-WT-infected cells. Gene names and RPKMs can be found in Supplemental table S1. **B.** Gene-set expression analysis (GSEA) of all genes expressed 2.5-fold higher in RH than in RH Δ *myr1* (green) or RH Δ *rop17* (purple), where either was lower than the FDR q-value threshold of 10^{-5} . The gene sets are ordered based on descending levels of significance (ascending q-values) for the cells infected with RH Δ *myr1*. **C.** As in B, except GSEA was performed on the genes that were expressed 2.5-fold lower in RH compared to RH Δ *myr1* and RH Δ *rop17* by the same criteria.

603

- Supplemental Table S1. List of the RPKM values of HFF infected with the respective strains.
1. Carruthers VB, Sibley LD (1997) Sequential protein secretion from three distinct organelles of *Toxoplasma gondii* accompanies invasion of human fibroblasts. Eur J Cell Biol 73: 114-123.
 2. Hakansson S, Carruthers V, Heuser J, Sibley D (1997) A putative role for MIC2 in gliding motility of *Toxoplasma gondii*. Molecular Parasitology Meeting VIII, MBL Woods Hole, MA: 421.
 3. Soldati D, Dubremetz JF, Lebrun M (2001) Microneme proteins: structural and functional requirements to promote adhesion and invasion by the apicomplexan parasite *Toxoplasma gondii*. Int J Parasitol 31: 1293-1302.
 4. Boothroyd JC, Dubremetz JF (2008) Kiss and spit: the dual roles of *Toxoplasma* rhoptries. Nat Rev Microbiol 6: 79-88.
 5. Tyler JS, Boothroyd JC (2011) The C-terminus of *Toxoplasma* RON2 provides the crucial link between AMA1 and the host-associated invasion complex. PLoS Pathog 7: e1001282.
 6. Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, et al. (2011) The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog 7: e1001276.
 7. Tonkin ML, Roques M, Lamarque MH, Pugniere M, Douguet D, et al. (2011) Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science 333: 463-467.
 8. Kimata I, Tanabe K (1987) Secretion by *Toxoplasma gondii* of an antigen that appears to become associated with the parasitophorous vacuole membrane upon invasion of the host cell. J Cell Sci 88 (Pt 2): 231-239.

- 627 9. Dubremetz JF (2007) Rhoptries are major players in *Toxoplasma gondii* invasion and host cell
628 interaction. Cell Microbiol 9: 841-848.
- 629 10. Bradley PJ, Sibley LD (2007) Rhoptries: an arsenal of secreted virulence factors. Curr Opin
630 Microbiol 10: 582-587.
- 631 11. Hakimi MA, Olias P, Sibley LD (2017) *Toxoplasma* Effectors Targeting Host Signaling and
632 Transcription. Clin Microbiol Rev 30: 615-645.
- 633 12. Kemp LE, Yamamoto M, Soldati-Favre D (2013) Subversion of host cellular functions by the
634 apicomplexan parasites. FEMS Microbiol Rev 37: 607-631.
- 635 13. El Hajj H, Demey E, Poncet J, Lebrun M, Wu B, et al. (2006) The ROP2 family of *Toxoplasma*
636 *gondii* rhoptry proteins: proteomic and genomic characterization and molecular modeling.
637 Proteomics 6: 5773-5784.
- 638 14. Zhao Y, Ferguson DJ, Wilson DC, Howard JC, Sibley LD, et al. (2009) Virulent *Toxoplasma gondii*
639 evade immunity-related GTPase-mediated parasite vacuole disruption within primed
640 macrophages. J Immunol 182: 3775-3781.
- 641 15. Fentress SJ, Behnke MS, Dunay IR, Mashayekhi M, Rommereim LM, et al. (2010)
642 Phosphorylation of immunity-related GTPases by a *Toxoplasma gondii*-secreted kinase
643 promotes macrophage survival and virulence. Cell Host Microbe 8: 484-495.
- 644 16. Steinfeldt T, Konen-Waisman S, Tong L, Pawlowski N, Lamkemeyer T, et al. (2010)
645 Phosphorylation of mouse immunity-related GTPase (IRG) resistance proteins is an evasion
646 strategy for virulent *Toxoplasma gondii*. PLoS Biol 8: e1000576.
- 647 17. Howard JC, Hunn JP, Steinfeldt T (2011) The IRG protein-based resistance mechanism in mice
648 and its relation to virulence in *Toxoplasma gondii*. Curr Opin Microbiol 14: 414-421.

- 649 18. Behnke MS, Fentress SJ, Mashayekhi M, Li LX, Taylor GA, et al. (2012) The polymorphic
650 pseudokinase ROP5 controls virulence in *Toxoplasma gondii* by regulating the active kinase
651 ROP18. PLoS Pathog 8: e1002992.
- 652 19. Fleckenstein MC, Reese ML, Konen-Waisman S, Boothroyd JC, Howard JC, et al. (2012) A
653 *Toxoplasma gondii* pseudokinase inhibits host IRG resistance proteins. PLoS Biol 10:
654 e1001358.
- 655 20. Niedelman W, Gold DA, Rosowski EE, Sprockholt JK, Lim D, et al. (2012) The rhoptry proteins
656 ROP18 and ROP5 mediate *Toxoplasma gondii* evasion of the murine, but not the human,
657 interferon-gamma response. PLoS Pathog 8: e1002784.
- 658 21. Etheridge RD, Alaganan A, Tang K, Lou HJ, Turk BE, et al. (2014) The *Toxoplasma* pseudokinase
659 ROP5 forms complexes with ROP18 and ROP17 kinases that synergize to control acute
660 virulence in mice. Cell Host Microbe 15: 537-550.
- 661 22. Sadak A, Taghy Z, Fortier B, Dubremetz JF (1988) Characterization of a family of rhoptry
662 proteins of *Toxoplasma gondii*. Mol Biochem Parasitol 29: 203-211.
- 663 23. Beckers CJM, Dubremetz JF, Mercereau-Puijalon O, Joiner KA (1994) The *Toxoplasma gondii*
664 rhoptry protein ROP2 is inserted into the parasitophorous vacuole membrane, surrounding
665 the intracellular parasite, and is exposed to the host cell cytoplasm. J Cell Biol 127: 947-961.
- 666 24. El Hajj H, Lebrun M, Fourmaux MN, Vial H, Dubremetz JF (2007) Inverted topology of the
667 *Toxoplasma gondii* ROP5 rhoptry protein provides new insights into the association of the
668 ROP2 protein family with the parasitophorous vacuole membrane. Cell Microbiol 9: 54-64.
- 669 25. Li JX, He JJ, Elsheikha HM, Chen D, Zhai BT, et al. (2019) *Toxoplasma gondii* ROP17 inhibits the
670 innate immune response of HEK293T cells to promote its survival. Parasitol Res.

- 671 26. Fox BA, Sanders KL, Rommereim LM, Guevara RB, Bzik DJ (2016) Secretion of Rhoptry and
672 Dense Granule Effector Proteins by Nonreplicating *Toxoplasma gondii* Uracil Auxotrophs
673 Controls the Development of Antitumor Immunity. PLoS Genet 12: e1006189.
- 674 27. Cesbron-Delauw MF, Lecordier L, Mercier C (1996) Role of secretory dense granule organelles
675 in the pathogenesis of *Toxoplasmosis*. Curr Top Microbiol Immunol 219: 59-65.
- 676 28. Charif H, Darcy F, Torpier G, Cesbron-Delauw MF, Capron A (1990) *Toxoplasma gondii*:
677 characterization and localization of antigens secreted from tachyzoites. Exp Parasitol 71:
678 114-124.
- 679 29. Leriche MA, Dubremetz JF (1990) Exocytosis of *Toxoplasma gondii* dense granules into the
680 parasitophorous vacuole after host cell invasion. Parasitol Res 76: 559-562.
- 681 30. Dubremetz JF, Achbarou A, Bermudes D, Joiner KA (1993) Kinetics and pattern of organelle
682 exocytosis during *Toxoplasma gondii*/host-cell interaction. Parasitol Res 79: 402-408.
- 683 31. Mercier C, Cesbron-Delauw MF, Sibley LD (1998) The amphipathic alpha helices of the
684 toxoplasma protein GRA2 mediate post-secretory membrane association. J Cell Sci 111:
685 2171-2180.
- 686 32. Mercier C, Howe DK, Mordue D, Lingnau M, Sibley LD (1998) Targeted disruption of the GRA2
687 locus in *Toxoplasma gondii* decreases acute virulence in mice. Infect Immun 66: 4176-4182.
- 688 33. Pernas L, Adomako-Ankomah Y, Shastri AJ, Ewald SE, Treeck M, et al. (2014) *Toxoplasma*
689 effector MAF1 mediates recruitment of host mitochondria and impacts the host response.
690 PLoS Biol 12: e1001845.
- 691 34. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, et al. (2011) Strain-specific activation of the NF-
692 kappaB pathway by GRA15, a novel *Toxoplasma gondii* dense granule protein. J Exp Med
693 208: 195-212.

- 694 35. Hakimi MA, Bougdour A (2015) *Toxoplasma's* ways of manipulating the host transcriptome via
695 secreted effectors. Curr Opin Microbiol 26: 24-31.
- 696 36. Bougdour A, Durandau E, Brenier-Pinchart MP, Ortet P, Barakat M, et al. (2013) Host cell
697 subversion by *Toxoplasma* GRA16, an exported dense granule protein that targets the host
698 cell nucleus and alters gene expression. Cell Host Microbe 13: 489-500.
- 699 37. Bougdour A, Tardieux I, Hakimi MA (2014) *Toxoplasma* exports dense granule proteins beyond
700 the vacuole to the host cell nucleus and rewires the host genome expression. Cell Microbiol
701 16: 334-343.
- 702 38. Gay G, Braun L, Brenier-Pinchart MP, Vollaire J, Josserand V, et al. (2016) *Toxoplasma gondii*
703 TglST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and
704 IFN-gamma-mediated host defenses. J Exp Med 213: 1779-1798.
- 705 39. Olias P, Etheridge RD, Zhang Y, Holtzman MJ, Sibley LD (2016) *Toxoplasma* Effector Recruits the
706 Mi-2/NuRD Complex to Repress STAT1 Transcription and Block IFN-gamma-Dependent
707 Gene Expression. Cell Host Microbe 20: 72-82.
- 708 40. He H, Brenier-Pinchart MP, Braun L, Kraut A, Touquet B, et al. (2018) Characterization of a
709 *Toxoplasma* effector uncovers an alternative GSK3/beta-catenin-regulatory pathway of
710 inflammation. Elife 7.
- 711 41. Naor A, Panas MW, Marino N, Coffey MJ, Tonkin CJ, et al. (2018) MYR1-Dependent Effectors Are
712 the Major Drivers of a Host Cell's Early Response to *Toxoplasma*, Including Counteracting
713 MYR1-Independent Effects. MBio 9.
- 714 42. Franco M, Panas MW, Marino ND, Lee MC, Buchholz KR, et al. (2016) A Novel Secreted Protein,
715 MYR1, Is Central to *Toxoplasma's* Manipulation of Host Cells. MBio 7: e02231-02215.

- 716 43. Marino ND, Panas MW, Franco M, Theisen TC, Naor A, et al. (2018) Identification of a novel
717 protein complex essential for effector translocation across the parasitophorous vacuole
718 membrane of *Toxoplasma gondii*. PLoS Pathog 14: e1006828.
- 719 44. Qiu W, Wernimont A, Tang K, Taylor S, Lunin V, et al. (2009) Novel structural and regulatory
720 features of rhoptry secretory kinases in *Toxoplasma gondii*. EMBO J 28: 969-979.
- 721 45. Labesse G, Gelin M, Bessin Y, Lebrun M, Papoin J, et al. (2009) ROP2 from *Toxoplasma gondii*: a
722 virulence factor with a protein-kinase fold and no enzymatic activity. Structure 17: 139-146.
- 723 46. Peixoto L, Chen F, Harb OS, Davis PH, Beiting DP, et al. (2010) Integrative genomic approaches
724 highlight a family of parasite-specific kinases that regulate host responses. Cell Host Microbe
725 8: 208-218.
- 726 47. Dunn JD, Ravindran S, Kim SK, Boothroyd JC (2008) The *Toxoplasma gondii* dense granule
727 protein GRA7 is phosphorylated upon invasion and forms an unexpected association with
728 the rhoptry proteins ROP2 and ROP4. Infect Immun 76: 5853-5861.
- 729 48. Hakansson S, Charron AJ, Sibley LD (2001) *Toxoplasma* vacuoles: a two-step process of
730 secretion and fusion forms the parasitophorous vacuole. EMBO J 20: 3132-3144.
- 731 49. Dou Z, McGovern OL, Di Cristina M, Carruthers VB (2014) *Toxoplasma gondii* ingests and digests
732 host cytosolic proteins. MBio 5: e01188-01114.
- 733 50. Treeck M, Sanders JL, Elias JE, Boothroyd JC (2011) The phosphoproteomes of *Plasmodium*
734 *falciparum* and *Toxoplasma gondii* reveal unusual adaptations within and beyond the
735 parasites' boundaries. Cell Host Microbe 10: 410-419.
- 736 51. Goldszmid RS, Coppens I, Lev A, Caspar P, Mellman I, et al. (2009) Host ER-parasitophorous
737 vacuole interaction provides a route of entry for antigen cross-presentation in *Toxoplasma*
738 *gondii*-infected dendritic cells. J Exp Med 206: 399-410.


- 739 52. Yamamoto M, Ma JS, Mueller C, Kamiyama N, Saiga H, et al. (2011) ATF6beta is a host cellular
740 target of the *Toxoplasma gondii* virulence factor ROP18. *J Exp Med* 208: 1533-1546.
- 741 53. Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC (2005) Identification of the moving
742 junction complex of *Toxoplasma gondii*: a collaboration between distinct secretory
743 organelles. *PLoS Pathog* 1: e17.
- 744 54. Besteiro S, Michelin A, Poncet J, Dubremetz JF, Lebrun M (2009) Export of a *Toxoplasma gondii*
745 rhoptry neck protein complex at the host cell membrane to form the moving junction during
746 invasion. *PLoS Pathog* 5: e1000309.
- 747 55. Fox BA, Ristuccia JG, Gigley JP, Bzik DJ (2009) Efficient gene replacements in *Toxoplasma gondii*
748 strains deficient for nonhomologous end joining. *Eukaryot Cell* 8: 520-529.
- 749 56. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9:
750 357-359.
- 751 57. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis
752 Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
753 *Genome Res* 20: 1297-1303.
- 754 58. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map
755 format and SAMtools. *Bioinformatics* 25: 2078-2079.
- 756 59. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, et al. (2012) A program for annotating and
757 predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of
758 *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 6: 80-92.
- 759 60. Shen B, Brown KM, Lee TD, Sibley LD (2014) Efficient gene disruption in diverse strains of
760 *Toxoplasma gondii* using CRISPR/CAS9. *MBio* 5: e01114-01114.

761
762


Figure 1

A


RH+
GRA16HA




RHΔmyr1+
GRA16HA



MF1.15+
GRA16HA



B



C

MF1.15

CHROMOSOME	POSITION	REFERENCE	VARIANT	COVERAGE	VARIANT FREQ	MUTATION	GENE ID	PRODUCT
TGGT1_chrV	892405	A	T	49	1	p.Phe13Ile	TGGT1_213420	RAP domain-containing protein
TGGT1_chrVIIa	797068	G	A	50	1	p.Val2706Ile	TGGT1_206580	formin FRM2
TGGT1_chrVIIb	3288140	A	T	35	0.97	p.Met350Lys	TGGT1_258580	roptry protein ROP17
TGGT1_chrVIII	3378623	T	A	48	1	p.Leu1402Gln	TGGT1_273580	hypothetical protein
TGGT1_chrIX	2863127	C	T	48	0.97	p.Val1133Ile	TGGT1_289190	tetratricopeptide repeat-containing protein
TGGT1_chrIX	2961195	A	T	43	1	p.Ser2Thr	TGGT1_289290	hypothetical protein
TGGT1_chrX	6416305	C	G	51	1	p.Cys1296Trp	TGGT1_214830	hypothetical protein
TGGT1_chrXII	3209479	A	C	39	0.97	p.Val125Gly	TGGT1_247350	thioredoxin domain-containing protein
TGGT1_chrXII	6166035	G	A	46	1	p.Ser291Phe	TGGT1_278205	hypothetical protein
TGGT1_chrX	1938795	T	G	41	1	p.Val701Gly	TGGT1_264670	DNA polymerase family B protein
TGGT1_chrVIII	5386411	T	C	49	1	p.Thr63Ala	TGGT1_270140	putative splicing factor DIM1

MF2.1b

CHROMOSOME	POSITION	REFERENCE	VARIANT	COVERAGE	VARIANT FREQ	MUTATION	GENE ID	PRODUCT
TGGT1_chrVIIa	3223402	A	G	40	1	p.Ile53Thr	TGGT1_202445	hypothetical protein
TGGT1_chrVIIb	3288737	G	C	39	1	p.Ser151*	TGGT1_258580	roptry protein ROP17
TGGT1_chrIX	2870406	T	C	49	1	p.Lys526Glu	TGGT1_289190	tetratricopeptide repeat-containing protein

Figure 2






Figure 3







Figure 4



C




Figure 5




Figure 6

A

Time	Condition 1	Condition 2
0 hr	RHΔ <i>rop17</i> GRA24MYC	RHΔ <i>myr1</i> mCherry
1 hr	RHΔ <i>myr1</i> mCherry	RHΔ <i>rop17</i> GRA24MYC
18 hr	fix for IFA	fix for IFA

B






Figure 7

A



B



C

